Biofrontera Bioscience GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.biofrontera.com

Clinical Trials

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Phase 3

Recruiting

Conditions: Actinic Keratoses

Interventions: Combination Product: BF-200 ALA and red light LED lamp
Combination Product: Vehicle and red light LED lamp

First Posted Date: 2022-12-22

Last Posted Date: 2024-11-07

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 165

Registration Number: NCT05662202

Locations: 🇺🇸
The Indiana Clinical Trials Center, PC, Plainfield, Indiana, United States
🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸
Alliance Dermatology & Mohs Center, Phoenix, Arizona, United States

and more 10 locations

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Phase 2

Recruiting

Conditions: Acne Vulgaris

Interventions: Combination Product: 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Combination Product: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Combination Product: 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product: 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

First Posted Date: 2021-10-18

Last Posted Date: 2024-06-26

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 126

Registration Number: NCT05080764

Locations: 🇺🇸
DelRicht Research, Baton Rouge, Louisiana, United States
🇺🇸
Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
Cosmetic Laser Dermatology, San Diego, California, United States

and more 7 locations

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Phase 1

Completed

Conditions: Keratosis, Actinic
Actinic Keratosis
Keratosis

Interventions: Combination Product: BF-200 ALA and red light LED lamp

First Posted Date: 2021-09-29

Last Posted Date: 2024-10-17

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 112

Registration Number: NCT05060237

Locations: 🇺🇸
Clinical Research Center of the Carolinas, Charleston, South Carolina, United States
🇺🇸
Laser and Skin Surgery Center of Indiana, Indianapolis, Indiana, United States
🇺🇸
Dermatology Practice, Greenwood Village, Colorado, United States

and more 6 locations

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Phase 1

Completed

Conditions: Actinic Keratoses

Interventions: Combination Product: BF-200 ALA and red light LED lamp

First Posted Date: 2020-03-24

Last Posted Date: 2021-11-11

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 48

Registration Number: NCT04319159

Locations: 🇺🇸
DermResearch Inc., Austin, Texas, United States

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Phase 3

Active, not recruiting

Conditions: Superficial Basal Cell Carcinoma

Interventions: Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)

First Posted Date: 2018-06-29

Last Posted Date: 2024-06-26

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 186

Registration Number: NCT03573401

Locations: 🇺🇸
AboutSkin Research, LLC, Greenwood Village, Colorado, United States
🇺🇸
University of Florida Dept of Dermatology, Gainesville, Florida, United States
🇺🇸
The Narrows Institute for Biomedical Research and Education, Inc., Brooklyn, New York, United States

and more 14 locations

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: BF-200 ALA
Drug: Vehicle

First Posted Date: 2016-06-14

Last Posted Date: 2017-04-06

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 122

Registration Number: NCT02799082

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: MAL Cream
Drug: Vehicle
Drug: BF-200 ALA

First Posted Date: 2016-06-14

Last Posted Date: 2017-04-28

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 571

Registration Number: NCT02799069

A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: BF-200 ALA 1%
Drug: BF-200 ALA 3%
Drug: BF-200 ALA 10%

First Posted Date: 2016-06-14

Last Posted Date: 2016-07-19

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 105

Registration Number: NCT02799030

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Phase 3

Completed

Conditions: Basal Cell Carcinoma (BCC)

Interventions: Drug: methyl-aminolevulinate
Drug: BF-200 ALA

First Posted Date: 2014-05-21

Last Posted Date: 2022-11-03

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 281

Registration Number: NCT02144077

Locations: 🇩🇪
Klinikum Vest GmbH, Recklinghausen, Westfalen-Lippe, Germany

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Phase 3

Completed

Conditions: Actinic Keratosis

Interventions: Drug: BF-200 ALA gel
Drug: Placebo to BF-200 ALA gel
Procedure: Photodynamic therapy with BF-RhodoLED

First Posted Date: 2013-10-21

Last Posted Date: 2023-07-28

Lead Sponsor: Biofrontera Bioscience GmbH

Target Recruit Count: 87

Registration Number: NCT01966120

Locations: 🇩🇪
Dermatologisches Zentrum Bonn Friedensplatz, Bonn, Germany

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy